Androgen deprivation therapy (ADT), a common treatment for men with prostate cancer, reduces testosterone production and causes side effects that negatively impact quality of life and reduce physical functionality.
Previous studies indicate that older men who take androgen deprivation therapy for prostate cancer are at an increased risk for diabetes and cardiovascular disease, but the relationship between the two among men of all ages is unclear.
06 and VCOG PR 01-03: The Timing Of Androgen Deprivation Therapy In Prostate Cancer Patients With A Rising PSA (TOAD) Collaborative Randomised Phase III Trial examined 293 patients with PSA relapse after definitive therapy to compare if immediate ADT versus delayed ADT affected OS.
One group of researchers found that primary androgen deprivation therapy fails to improve either overall or disease-specific survival in this patient population, yet it still is widely used as the initial treatment for localized disease.
Researchers ultimately determined that intermittent androgen deprivation does not achieve comparable survival rates compared to complete androgen deprivation therapy, though it does provide small improvements in quality of life (i.
An option for these patients is androgen deprivation therapy, which reduces testosterone (a hormone that may increase the growth of prostate cancer); however, the treatment has significant side effects and is not effective for all who use it.
This population-based cohort study examined whether androgen deprivation therapy (orchiectomy or luteinizing hormone-releasing hormone) is associated with improved survival among elderly men with localized prostate cancer, when compared with conservative management (i.